AstraZeneca advances weight-loss pill to take aim at obesity leaders ○
found
a story from Financial Times ✅ › Financial Times
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli Lilly
since
auto-detected in 162 stories
36 hours ago
Pill from drugmaker would put it into competition with market leaders Novo Nordisk and Eli Lilly
2 days ago
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why ○
"I think the majority view is that Lilly is pulling away, kind of Secretariat-like," Jim Cramer said Monday.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage ⊕
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
13 days ago
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans ⊕
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
14 days ago
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know ⊕
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
15 days ago
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals ⊕
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
16 days ago
Want to hop off the AI trade? Goldman says buy these stocks that have nothing to do with it ⊕
Stocks such as Eli Lilly and Fortinet are less correlated to the artificial intelligence frenzy, according to Goldman Sachs.
22 days ago
Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefited from his policies ⊕⊕
Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies
Hundreds of thousands of dollars were invested in Eli Lil…
37 days ago
What's behind Eli Lilly's down-and-up day after last week's post-earnings surge ○
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance ⊕
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.